Virtual Tumor Board: Checkpoint Blockade in the Adjuvant and Neoadjuvant Settings: Key Considerations for the Surgical Oncologist

In this recorded virtual tumor board, faculty discuss the use of neoadjuvant and adjuvant immunotherapy for esophageal and gastric cancers and discuss how to properly incorporate immunotherapies into care plans based on the latest clinical trial data and recommendations. The role of biomarkers in identifying eligible patients and ongoing clinical trials that will further impact the use of immunotherapies in gastroesophageal cancers is also highlighted.

Virtual Tumor Board: Checkpoint Blockade in the Adjuvant and Neoadjuvant Settings: Key Considerations for the Surgical Oncologist

Live Virtual Meeting

This is a case-based, multi-disciplinary virtual tumor board activity meant to provide surgical oncologists with information relative to treating the cancer patient.

At the conclusion of this activity, participants should be able to:

• Describe the mechanistic rationale for the role of immunotherapies in earlier stage gastric and esophageal cancer

• Summarize available and ongoing clinical trial data on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable gastric and esophageal cancers

• Translate the latest clinical trial data to identify appropriate patients with significant recurrence risk who may benefit from approved or emerging uses of neoadjuvant or adjuvant immunotherapy

• Assess emerging biomarkers for ICIs in the early disease setting and their potential predictive role in assessing long term benefits

Faculty: G. Travis Clifton, MD (Moderator), Mihir M. Shah, MD (Panelist), Salma Jabbour, MD (Panelist), Howard Hochster, MD (Panelist), Onkar Khullar, MD, MSc (Panelist)

Release Date: December 06, 2021

Expiration Date: December 06, 2021

CME/CE is no longer available for this activity

Checkpoint Blockade in the Adjuvant and Neoadjuvant Settings: Key Considerations for the Surgical Oncologist

Case-based Education

A multidisciplinary panel of faculty discuss the use of neoadjuvant and adjuvant immunotherapy for esophageal and gastric cancers in this recorded virtual tumor board. Throughout the case discussions, faculty discuss how to properly incorporate immunotherapies into care plans based on the latest clinical trial data and recommendations. The faculty also highlight the role of biomarkers in identifying eligible patients and ongoing clinical trials that will further impact the use of immunotherapies in gastroesophageal cancers.

"As of May 27, 2022, the FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status."

Faculty: G. Travis Clifton, MD (Moderator), Mihir M. Shah, MD (Panelist), Salma Jabbour, MD (Panelist), Howard Hochster, MD (Panelist), Onkar Khullar, MD, MSc (Panelist)

Release Date: December 22, 2021

Expiration Date: December 22, 2022

CME/CE is no longer available for this activity